CNS Drugs

, Volume 24, Issue 3, pp 207–225

The Efficacy of Hypericum perforatum (St John’s Wort) for the Treatment of Premenstrual Syndrome

A Randomized, Double-Blind, Placebo-Controlled Trial
  • Sarah Canning
  • Mitch Waterman
  • Nic Orsi
  • Julie Ayres
  • Nigel Simpson
  • Louise Dye
Original Research Article

Abstract

Background: Premenstrual syndrome (PMS) is a common condition. Some of the most widely prescribed medications are selective serotonin reuptake inhibitors (SSRIs), based on the hypothesized role of serotonin in the production of PMS symptoms. PMS sufferers, especially those experiencing mild to moderate symptoms, are often reluctant to take this form of medication and instead buy over-the-counter preparations to treat their symptoms, for which the evidence base with regard to efficacy is limited. Hypericum perforatum (St John’s wort) influences the serotonergic system. As such, this widely available herbal remedy deserves attention as a PMS treatment.

Objective: To investigate the effectiveness of Hypericum perforatum on symptoms of PMS.

Study design: This randomized, double-blind, placebo-controlled, crossover study was conducted between November 2005 and June 2007.

Setting: Institute of Psychological Sciences, University of Leeds, Leeds, UK.

Participants: 36 women aged 18–45 years with regular menstrual cycles (25–35 days), who were prospectively diagnosed with mild PMS.

Intervention: Women who remained eligible after three screening cycles (n = 36) underwent a two-cycle placebo run-in phase. They were then randomly assigned to receive Hypericum perforatum tablets 900 mg/day (standardized to 0.18% hypericin; 3.38% hyperforin) or identical placebo tablets for two menstrual cycles. After a placebo-treated washout cycle, the women crossed over to receive placebo or Hypericum perforatum for two additional cycles.

Main outcome measures: Symptoms were rated daily throughout the trial using the Daily Symptom Report. Secondary outcome measures were the State Anxiety Inventory, Beck Depression Inventory, Aggression Questionnaire and Barratt Impulsiveness Scale. Plasma hormone (follicle-stimulating hormone [FSH], luteinizing hormone [LH], estradiol, progesterone, prolactin and testosterone) and cytokine (interleukin [IL]-1β, IL-6, IL-8, interferon [IFN]-γ and tumour necrosis factor [TNF]-α) levels were measured in the follicular and luteal phases during Hypericum perforatum and placebo treatment.

Results: Hypericum perforatum was statistically superior to placebo in improving physical and behavioural symptoms of PMS (p < 0.05). There were no significant effects of Hypericum perforatum compared with placebo treatment for mood- and pain-related PMS symptoms (p > 0.05). Plasma hormone (FSH, LH, estradiol, progesterone, prolactin and testosterone) and cytokine (IL-1β, IL-6, IL-8, IFNγ and TNFα) levels, and weekly reports of anxiety, depression, aggression and impulsivity, also did not differ significantly during the Hypericum perforatum and placebo cycles (p > 0.05).

Conclusion: Daily treatment with Hypericum perforatum was more effective than placebo treatment for the most common physical and behavioural symptoms associated with PMS. As proinflammatory cytokine levels did not differ significantly between Hypericum perforatum and placebo treatment, these beneficial effects are unlikely to be produced through this mechanism of action alone. Further work is needed to determine whether pain- and mood-related PMS symptoms benefit from longer treatment duration.

Trial registration number (International Standard Randomised Controlled Trial Number Register) ISRCTN31487459

References

  1. 1.
    Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology 2003 Aug; 28Suppl. 3: 25–37PubMedCrossRefGoogle Scholar
  2. 2.
    Halbreich U, Backstrom T, Eriksson E, et al. Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies. Gynecol Endocrinol 2007 Mar; 23(3): 123–30PubMedCrossRefGoogle Scholar
  3. 3.
    Reed SC, Levin FR, Evans SM. Changes in mood, cognitive performance and appetite in the late luteal and follicular phases of the menstrual cycle in women with and without PMDD (premenstrual dysphoric disorder). Horm Behav 2008 Jun; 54(1): 185–93PubMedCrossRefGoogle Scholar
  4. 4.
    Borenstein JE, Dean BB, Yonkers KA, et al. Using the daily record of severity of problems as a screening instrument for premenstrual syndrome. Obstet Gynecol 2007 May; 109(5): 1068–75PubMedCrossRefGoogle Scholar
  5. 5.
    Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol 2004 Oct; 104(4): 845–59PubMedCrossRefGoogle Scholar
  6. 6.
    Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; Department of Health and Human Services, 1994Google Scholar
  7. 7.
    Steiner M, Wilkins A. Diagnosis and assessment of premenstrual dysphoria. Psychiatr Ann 1996 Sep; 26(9): 571–5Google Scholar
  8. 8.
    Ussher JM. Processes of appraisal and coping in the development and maintenance of premenstrual dysphoric disorder. J Community Appl Soc Psychol 2002 Sep–Oct; 12(5): 309–22CrossRefGoogle Scholar
  9. 9.
    Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoric disorder. CNS Drugs 2000 Apr; 13(4): 287–304CrossRefGoogle Scholar
  10. 10.
    Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry 2000; 61Suppl. 12: 17–21PubMedGoogle Scholar
  11. 11.
    Ussher JM. The ongoing silencing of women in families: an analysis and rethinking of premenstrual syndrome and therapy. J Fam Ther 2003 Nov; 25(4): 388–405CrossRefGoogle Scholar
  12. 12.
    Ainscough CE. Premenstrual emotional changes: a prospective study of symptomatology in normal women. J Psychosom Res 1990; 34(1): 35–45PubMedCrossRefGoogle Scholar
  13. 13.
    Gallant SJ, Popiel DA, Hoffman DM, et al. Using daily ratings to confirm premenstrual syndrome/late luteal phase dysphoric disorder: part II. What makes a ‘real’ difference? Psychosom Med 1992 Mar–Apr; 54(2): 167–81PubMedGoogle Scholar
  14. 14.
    Ussher JM. The role of premenstrual dysphoric disorder in the subjectification of women. J Med Humanit 2003 Jun; 24(1–2): 131–46CrossRefGoogle Scholar
  15. 15.
    Bancroft J, Williamson L, Warner P, et al. Perimenstrual complaints in women complaining of PMS, menorrhagia, and dysmenorrhea: toward a dismantling of the premenstrual syndrome. Psychosom Med 1993 Mar–Apr; 55(2): 133–45PubMedGoogle Scholar
  16. 16.
    Morse CA, Dennerstein L, Varnavides K, et al. Menstrual cycle symptoms: comparison of a non-clinical sample with a patient group. J Affect Disord 1988 Jan–Feb; 14(1): 41–50PubMedCrossRefGoogle Scholar
  17. 17.
    Dimmock PW, Wyatt KM, Jones PW, et al. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet 2000 Sep; 356(9236): 1131–6PubMedCrossRefGoogle Scholar
  18. 18.
    Wyatt KM, Dimmock PW, O’Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev 2002; (4): CD001396Google Scholar
  19. 19.
    Connolly M. Premenstrual syndrome: an update on definitions, diagnosis and management. Adv Psychiatr Treat 2001; 7(6): 469–77CrossRefGoogle Scholar
  20. 20.
    Bendich A. The potential for dietary supplements to reduce premenstrual syndrome (PMS) symptoms. J Am Coll Nutr 2000 Feb; 19(1): 3–12PubMedGoogle Scholar
  21. 21.
    Canning S, Waterman M, Dye L. Dietary supplements and herbal remedies for premenstrual syndrome (PMS): a systematic research review of the evidence for their efficacy. J Reprod Infant Psychol 2006 Nov; 24(4): 363–78CrossRefGoogle Scholar
  22. 22.
    Domoney CL, Vashisht A, Studd JW. Premenstrual syndrome and the use of alternative therapies. Ann N Y Acad Sci 2003 Nov; 997: 330–40PubMedCrossRefGoogle Scholar
  23. 23.
    Eriksson E, Endicott J, Andersch B. New perspectives on the treatment of premenstrual syndrome and premenstrual dysphoric disorder. Arch Womens Ment Health 2002; 4(4): 111–9CrossRefGoogle Scholar
  24. 24.
    Blake F, Salkovskis P, Gath D, et al. Cognitive therapy for premenstrual syndrome: a controlled trial. J Psychosom Res 1998 Oct; 45(4): 307–18PubMedCrossRefGoogle Scholar
  25. 25.
    Hunter M, Ussher J, Cariss M, et al. A randomised comparison of psychological (cognitive behaviour therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder. J Psychosom Obstet Gynaecol 2002 Sep; 23: 193–9PubMedCrossRefGoogle Scholar
  26. 26.
    Kirkby RJ. Changes in premenstrual symptoms and irrational thinking following cognitive-behavioral coping skills training. J Consult Clin Psychol 1994 Oct; 62(5): 1026–32PubMedCrossRefGoogle Scholar
  27. 27.
    Morse CA, Dennerstein L, Farrell E, et al. A comparison of hormone therapy, coping skills training, and relaxation for the relief of premenstrual syndrome. J Behav Med 1991 Oct; 14(5): 469–89PubMedCrossRefGoogle Scholar
  28. 28.
    Goodale IL, Domar AD, Benson H. Alleviation of premenstrual syndrome symptoms with the relaxation response. Obstet Gynecol 1990 Apr; 74(4): 649–55Google Scholar
  29. 29.
    Anson O. Exploring the bio-psycho-social approach to premenstrual experiences. Soc Sci Med 1999 Jul; 49(1): 67–80PubMedCrossRefGoogle Scholar
  30. 30.
    Keye Jr WR, Trunnell EP. A biopsychosocial model of premenstrual syndrome. Int J Fertil 1986 Sep–Oct; 31(4): 259–62PubMedGoogle Scholar
  31. 31.
    Rubinow DR, Schmidt PJ. Models for the development and expression of symptoms in premenstrual syndrome. Psychiatr Clin North Am 1989 Mar; 12(1): 53–68PubMedGoogle Scholar
  32. 32.
    Ussher JM, Hunter M, Cariss M. A women-centred psychological intervention for premenstrual symptoms, drawing on cognitive-behavioural and narrative therapy. Clin Psychol Psychother 2002; 9(5): 319–31CrossRefGoogle Scholar
  33. 33.
    Walker AF. Theory and methodology in premenstrual syndrome research. Soc Sci Med 1995 Sep; 41(6): 793–800PubMedCrossRefGoogle Scholar
  34. 34.
    Bäckström T, Carstensen H. Estrogen and progesterone in plasma in relation to premenstrual tension. J Steroid Biochem 1974 May; 5(3): 257–60PubMedCrossRefGoogle Scholar
  35. 35.
    Horrobin DF. The role of essential fatty acids and prostaglandins in the premenstrual syndrome. J Reprod Med 1983 Jul; 28(7): 465–8PubMedGoogle Scholar
  36. 36.
    Shamberger RJ. Calcium, magnesium, and other elements in the red blood cells and hair of normals and patients with premenstrual syndrome. Biol Trace Elem Res 2003 Aug; 94(2): 123–9PubMedCrossRefGoogle Scholar
  37. 37.
    Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. J Clin Endocrinol Metab 1995 Jul; 80(7): 2227–32PubMedCrossRefGoogle Scholar
  38. 38.
    Abraham GE, Lubran MM. Serum and red cell magnesium levels in patients with premenstrual tension. Am J Clin Nutr 1981 Nov; 34(11): 2364–6PubMedGoogle Scholar
  39. 39.
    Brush MG, Watson SJ, Horrobin DF, et al. Abnormal essential fatty acid levels in plasma of women with premenstrual syndrome. Am J Obstet Gynecol 1984 Oct; 150(4): 363–6PubMedGoogle Scholar
  40. 40.
    Carroll BJ, Steiner M. The psychobiology of premenstrual dysphoria: the role of prolactin. Psychoneuroendocrinology 1978 Apr; 3(2): 171–80PubMedCrossRefGoogle Scholar
  41. 41.
    Halbreich U. Premenstrual dysphoric disorders: a diversified cluster of vulnerability traits to depression. Acta Psychiatr Scand 1997 Mar; 95(3): 169–76PubMedCrossRefGoogle Scholar
  42. 42.
    Rapkin AJ. The role of serotonin in premenstrual syndrome. Clin Obstet Gynecol 1992 Sep; 35(3): 629–36PubMedCrossRefGoogle Scholar
  43. 43.
    Ashby CR, Carr LA, Cook CL, et al. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity on premenstrual syndrome. Biol Psychiatry 1988 Jun; 24(2): 225–33PubMedCrossRefGoogle Scholar
  44. 44.
    Rapkin AJ, Edelmuth E, Chang LC, et al. Whole-blood serotonin in premenstrual syndrome. Obstet Gynecol 1987 Oct; 70(4): 533–7PubMedGoogle Scholar
  45. 45.
    Rasgon N, McGuire M, Tanavoli S, et al. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome. Fertil Steril 2000 Jan; 73(1): 144–9PubMedCrossRefGoogle Scholar
  46. 46.
    Taylor DL, Mathew RJ, Ho BT, et al. Serotonin levels and platelet uptake during premenstrual tension. Neuropsychobiology 1984; 12(1): 16–8PubMedCrossRefGoogle Scholar
  47. 47.
    Cleare AJ, Bond AJ. The effects of tryptophan depletion and enhancement on subjective and behavioural aggression in normal subjects. Psychopharmacology 1995 Mar; 118(1): 72–81PubMedCrossRefGoogle Scholar
  48. 48.
    Ho HP, Olsson M, Westberg L, et al. The serotonin reuptake inhibitor fluoxetine reduces sex steroid-related aggression in female rats: an animal model of premenstrual irritability? Neuropsychopharmacology 2001 May; 24(5): 502–10PubMedCrossRefGoogle Scholar
  49. 49.
    Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000; 61Suppl. 6: 4–6PubMedGoogle Scholar
  50. 50.
    Kahn RS, van Praag HM, Wetzler S, et al. Serotonin and anxiety revisited. Biol Psychiatry 1988 Jan; 23(2): 189–208PubMedCrossRefGoogle Scholar
  51. 51.
    Russo S, Kema IP, Haagsma EB, et al. Irritability rather than depression during interferon treatment is linked to increased tryptophan catabolism. Psychosom Med 2005 Sep–Oct; 67(5): 773–7PubMedCrossRefGoogle Scholar
  52. 52.
    Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002 Feb; 22(1): 86–90PubMedCrossRefGoogle Scholar
  53. 53.
    Gemma C, Imeri L, De Simoni MG, et al. Interleukin-1 induces changes in sleep, brain temperature, and serotonergic metabolism. Am J Physiol 1997 Feb; 272 (2 Pt 2): R601–6PubMedGoogle Scholar
  54. 54.
    Gemma C, Imeri L, Opp MR. Serotonergic activation stimulates the pituitary-adrenal axis and alters interleukin-1 (IL-1) mRNA expression in rat brain. Psychoneuroendocrinology 2003 Oct; 28(7): 875–84PubMedCrossRefGoogle Scholar
  55. 55.
    Linthorst AC, Flachskamm C, Holsboer F, et al. Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology 1994 Aug; 135(2): 520–32PubMedCrossRefGoogle Scholar
  56. 56.
    O’Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol 2004 Aug; 19(6): 397–403PubMedCrossRefGoogle Scholar
  57. 57.
    Pousset F, Fournier J, Legoux P, et al. Effect of serotonin on cytokine mRNA expression in rat hippocampal astrocytes. Brain Res Mol Brain Res 1996 May; 38(1): 54–62PubMedCrossRefGoogle Scholar
  58. 58.
    Silverman DH, Imam K, Karnovsky ML. Muramyl peptide/ serotonin receptors in brain-derived preparations. Pept Res 1989 Sep–Oct; 2(5): 338–44PubMedGoogle Scholar
  59. 59.
    Gorai I, Taguchi Y, Chaki O, et al. Serum soluble inter-leukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J Clin Endocrinol Metab 1998 Feb; 83(2): 326–32PubMedCrossRefGoogle Scholar
  60. 60.
    Vrieze A, Postma DS, Kerstjens HA. Perimenstrual asthma: a syndrome without known cause or cure. J Allergy Clin Immunol 2003 Aug; 112(2): 271–82PubMedCrossRefGoogle Scholar
  61. 61.
    Cannon JG, Dinarello CA. Increased plasma interleukin-1 activity in women after ovulation. Science 1985 Mar; 227(4691): 1247–9PubMedCrossRefGoogle Scholar
  62. 62.
    Polan ML, Kuo A, Loukides J, et al. Cultured human luteal peripheral monocytes secrete increased levels of interleukin-1. J Clin Endocrinol Metab 1990 Feb; 70(2): 480–4PubMedCrossRefGoogle Scholar
  63. 63.
    Konecna L, Yan MS, Miller LE, et al. Modulation of IL-6 production during the menstrual cycle in vivo and in vitro. Brain Behav Immun 2000 Mar; 14(1): 49–61PubMedCrossRefGoogle Scholar
  64. 64.
    Maes M, Meltzer H, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6 receptor, soluble interleukin-2 receptor and transferrin receptor in major depression. J Affect Disord 1995 Aug; 34(4): 301–9PubMedCrossRefGoogle Scholar
  65. 65.
    Schlatter J, Ortuno F, Cervera-Enguix S. Differences in interleukins’ patterns between dysthymia and major depression. Eur Psychiatry 2001 Aug; 16(5): 317–9PubMedCrossRefGoogle Scholar
  66. 66.
    Connor TJ, Song C, Leonard BE, et al. An assessment of the effects of central interleukin-1 beta, -2, -6, and tumor necrosis factor-alpha administration on some behavioural, neurochemical, endocrine and immune parameters in the rat. Neuroscience 1998 Jun; 84(3): 923–33PubMedCrossRefGoogle Scholar
  67. 67.
    Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000 May; 157(5): 683–94PubMedCrossRefGoogle Scholar
  68. 68.
    Martelletti P, Granata M, Giacovazzo M. Serum interleukin-1 beta is increased in cluster headache. Cephalalgia 1993 Oct; 13(5): 343–5PubMedCrossRefGoogle Scholar
  69. 69.
    Kapas L, Krueger JM. Tumor necrosis factor-beta induces sleep, fever, and anorexia. Am J Physiol Regul Integr Comp Physiol 1992 Sep; 263 (3 Pt 2): 703–7Google Scholar
  70. 70.
    Vgontzas AN, Bixler EO, Lin HM, et al. IL-6 and its circadian secretion in humans. Neuroimmunomodulation 2005 May; 12(3): 131–40PubMedCrossRefGoogle Scholar
  71. 71.
    Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001 May; 58(5): 445–52PubMedCrossRefGoogle Scholar
  72. 72.
    Menkes DB, MacDonald JA. Interferons, serotonin and neurotoxicity. Psychol Med 2000 Mar; 30(2): 259–68PubMedCrossRefGoogle Scholar
  73. 73.
    Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 2001 Jan; 16(1): 95–103PubMedCrossRefGoogle Scholar
  74. 74.
    Sluzewska A, Rybakowski JK, Laciak M, et al. Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci 1995 Jul; 762: 474–6PubMedCrossRefGoogle Scholar
  75. 75.
    Van Gool AR, Fekkes D, Kruit WH, et al. Serum amino acids, biopterin and neopterin during long-term immunotherapy with interferon-alpha in high-risk melanoma patients. Psychiatry Res 2003 Jul; 119(1–2): 125–32Google Scholar
  76. 76.
    Calapai G, Crupi A, Firenzuoli F, et al. Serotonin, norepinephrine and dopamine involvement in the anti-depressant action of hypericum perforatum. Pharmacopsychiatry 2001 Mar; 34(2): 45–9PubMedCrossRefGoogle Scholar
  77. 77.
    Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998 Jun; 31Suppl. 1: 16–21PubMedCrossRefGoogle Scholar
  78. 78.
    Teufel-Mayer R, Gleitz J. Effects of long-term administration of hypericum extracts on the affinity and density of the central serotonergic 5-HT1 A and 5-HT2 A receptors. Pharmacopsychiatry 1997 Sep; 30Suppl. 2: 113–6PubMedCrossRefGoogle Scholar
  79. 79.
    Fiebich BL, Hollig A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St. John’s wort extracts. Pharmacopsychiatry 2001 Jul; 34Suppl. 1: S26–8PubMedCrossRefGoogle Scholar
  80. 80.
    Thiele B, Brink I, Ploch M. Modulation of cytokine expression by hypericum extract. J Geriatr Psychiatry Neurol 1994 Oct; 7Suppl. 1: S60–2PubMedCrossRefGoogle Scholar
  81. 81.
    Clement K, Covertson CR, Johnson MJ, et al. St John’s wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 2006 Jul–Aug; 20(4): 197–203PubMedGoogle Scholar
  82. 82.
    Gaster B, Holroyd J. St John’s wort for depression: a systematic review. Arch Intern Med 2000 Jan; 160(2): 152–8PubMedCrossRefGoogle Scholar
  83. 83.
    Kim HL, Streltzer J, Goebert D. St John’s wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999 Sep; 187(9): 532–8PubMedCrossRefGoogle Scholar
  84. 84.
    Williams Jr JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000 May; 132(9): 743–56PubMedGoogle Scholar
  85. 85.
    Agha-Hosseini M, Kashani L, Aleyaseen A, et al. Crocus sativus L. (saffron) in the treatment of premenstrual syndrome: a double-blind, randomised and placebo-controlled trial. BJOG 2008 Mar; 115(4): 515–9PubMedCrossRefGoogle Scholar
  86. 86.
    Hicks SM, Walker AF, Gallagher J, et al. The significance of “nonsignificance” in randomized controlled studies: a discussion inspired by a double-blinded study on St. John’s wort (Hypericum perforatum L.) for premenstrual symptoms. J Altern Complement Med 2004 Dec; 10(6): 925–32Google Scholar
  87. 87.
    Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995 Jun; 332(23): 1529–34PubMedCrossRefGoogle Scholar
  88. 88.
    Pakgohar M, Mehran A, Salehi MS, et al. Comparison of hypericum perforatum and placebo in treatment of physical symptoms of premenstrual syndrome [in Persian]. HAYAT J Tehran Fac Nurs Midwifery 2004; 10(22): 99Google Scholar
  89. 89.
    Pakgohar M, Ahmadi M, Surmaghi MH, et al. Effect of Hypericum perforatum L. for treatment of premenstrual syndrome [in Persian]. J Med Plants 2005 Sep; 4(15): 33–42Google Scholar
  90. 90.
    Bennett Jr DA, Phun L, Polk JF, et al. Neuropharmacology of St. John’s wort (Hypericum). Ann Pharmacother 1998 Nov;32(11): 1201–8PubMedCrossRefGoogle Scholar
  91. 91.
    Miller AL. St. John’s wort (Hypericum perforatum): clinical effects on depression and other conditions. Altern Med Rev 1998 Feb; 3(1): 18–26PubMedGoogle Scholar
  92. 92.
    Montgomery S, Hubener W, Gregoleit H. Efficacy and tolerability of St John’s wort extract compared with placebo in patients with a mild to moderate depressive disorder. Phytomedicine 2000; 7Suppl. 2: 107Google Scholar
  93. 93.
    Shelton RC, Keller MB, Gelenberg A, et al. Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 2001 Apr; 285(15): 1978–86PubMedCrossRefGoogle Scholar
  94. 94.
    Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996 Nov; 65(2): 97–106PubMedCrossRefGoogle Scholar
  95. 95.
    Hamilton JA, Parry BL, Alagna S, et al. Premenstrual mood changes: a guide to evaluation and treatment. Psychiatr Ann 1984 Jun; 14(6): 426–35Google Scholar
  96. 96.
    NIMH Workshop on Pre-menstrual Syndrome. Co-sponsored by the Centre for Studies of Affective Disorders and the Psychobiological Processes and Behavioral Medicine Section. Rockville (MD): 1983 Apr: 14-15Google Scholar
  97. 97.
    Frye GM, Silverman SD. Is it premenstrual syndrome? Keys to focused diagnosis, therapies for multiple symptoms. Postgrad Med 2000 May; 107(5): 151–9PubMedCrossRefGoogle Scholar
  98. 98.
    Lampe L. Antidepressants: not just for depression. Aust Prescr 2005 Aug; 28(4): 91–3Google Scholar
  99. 99.
    Pearlstein TB. Hormones and depression: what are the facts about premenstrual syndrome, menopause, and hormone replacement therapy? Am J Obstet Gynecol 1995 Aug; 173(2): 646–53PubMedCrossRefGoogle Scholar
  100. 100.
    Wyatt KM, Dimmock PW, Frischer M, et al. Prescribing patterns in premenstrual syndrome. BMC Womens Health 2002 Jun; 2(4): 1–8Google Scholar
  101. 101.
    Landen M, Eriksson E. How does premenstrual dysphoric disorder relate to depression and anxiety disorders? Depress Anxiety 2003; 17(3): 122–9PubMedCrossRefGoogle Scholar
  102. 102.
    Quah-Smith JI, Tang WM, Russell J. Laser acupuncture for mild to moderate depression in a primary care setting: a randomised controlled trial. Acupunct Med 2005 Sep; 23(3): 103–11PubMedCrossRefGoogle Scholar
  103. 103.
    Nielson A, Williams T. Depression in ambulatory medical patients, prevalence by self-report questionnaire and recognition by non-psychiatric physicians. Arch Gen Psychiatry 1980; 37: 999–1004CrossRefGoogle Scholar
  104. 104.
    Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961 Jun; 4: 561–71PubMedCrossRefGoogle Scholar
  105. 105.
    Sheenan-Dare RA, Henderson MJ, Cotterill JA. Anxiety and depression in patients with chronic urticaria and generalised pruritus. Br J Dermatol 1990; 123(6): 769–74CrossRefGoogle Scholar
  106. 106.
    Spielberger CD. Manual for the State-Trait Anxiety Inventory: STAI (Form Y). Palo Alto (CA): Consulting Psychologists Press, 1983Google Scholar
  107. 107.
    Pocock SJ. Clinical trials: a practical approach. Chichester: John Wiley, 1983Google Scholar
  108. 108.
    Chisholm G, Jung SO, Cumming CE, et al. Premenstrual anxiety and depression: comparison of objective psychological tests with retrospective questionnaire. Acta Psychiatr Scand 1990 Jan; 81(1): 52–7PubMedCrossRefGoogle Scholar
  109. 109.
    Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology 2003 Aug; 28Suppl. 3: 55–99CrossRefGoogle Scholar
  110. 110.
    Warner P, Bancroft J. Factors related to self-reporting of the pre-menstrual syndrome. Br J Psychiatry 1990 Aug; 157: 249–60PubMedCrossRefGoogle Scholar
  111. 111.
    Hartlage SA, Arduino KE. Toward the content validity of premenstrual dysphoric disorder: do anger and irritability more than depressed mood represent treatment-seekers’ experience? Psychol Rep 2002 Feb; 90(1): 189–202PubMedCrossRefGoogle Scholar
  112. 112.
    Buss AH, Perry M. The Aggression Questionnaire. J Pers Soc Psychol 1992 Sep; 63(3): 452–9PubMedCrossRefGoogle Scholar
  113. 113.
    Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 1995 Nov; 51(6): 768–74PubMedCrossRefGoogle Scholar
  114. 114.
    Bryant M, Cassidy A, Hill C, et al. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005 May; 93(5): 731–9PubMedCrossRefGoogle Scholar
  115. 115.
    Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999 Oct; 56(10): 932–9PubMedCrossRefGoogle Scholar
  116. 116.
    FitzGerald SP, Lamont JV, McConnell RI, et al. Development of a high-throughput automated analyzer using biochip array technology. Clin Chem 2005 Jul; 51(7): 1165–76PubMedCrossRefGoogle Scholar
  117. 117.
    Hildesheim A, Ryan RL, Rinehart E, et al. Simultaneous measurement of several cytokines using small volumes of biospecimens. Cancer Epidemiol Biomarkers Prev 2002 Nov; 11(11): 1477–84PubMedGoogle Scholar
  118. 118.
    Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. BJOG 2000 Jul; 107(7): 870–6PubMedCrossRefGoogle Scholar
  119. 119.
    Rosenthal R, Rosnow RL. Essentials of behavioral research: methods and data analysis. 2nd ed. Singapore: McGraw-Hill, 1999Google Scholar
  120. 120.
    Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications, 1987Google Scholar
  121. 121.
    Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997 Aug; 17(4): 261–6PubMedCrossRefGoogle Scholar
  122. 122.
    Carlson NR. Foundations of Physiological Psychology. Boston (MA): Allyn and Bacon, 1988Google Scholar
  123. 123.
    Dantzer R, Wollman E, Vitkovic L, et al. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999 Jul; 4(4): 328–32PubMedCrossRefGoogle Scholar
  124. 124.
    Smith RS. The macrophage theory of depression. Med Hypotheses 1991 Aug; 35(4): 298–306PubMedCrossRefGoogle Scholar
  125. 125.
    Yonkers KA, O’Brien PMS, Eriksson E. Premenstrual syndrome. Lancet 2008 Apr; 371(9619): 1200–10PubMedCrossRefGoogle Scholar
  126. 126.
    Nangia M, Syed W, Doraiswamy PM. Efficacy and safety of St. John’s wort for the treatment of major depression. Public Health Nutr 2000; 3(4A): 487–94PubMedCrossRefGoogle Scholar
  127. 127.
    Raffa RB. Screen of receptor and uptake-site activity of hypericin component of St. John’s wort reveals sigma receptor binding. Life Sci 1998 Mar; 62(16): PL265–70PubMedCrossRefGoogle Scholar
  128. 128.
    Lester NA, Keel PA, Lipson SF. Symptom fluctuation in bulimia nervosa: relation to menstrual-cycle phase and cortisol levels. Psychol Med 2003; 33(1): 51–60PubMedCrossRefGoogle Scholar
  129. 129.
    Price WA, Torem MS, DiMarzio LR. Premenstrual exacerbation of bulimia. Psychosomatics 1987; 28: 378–9PubMedCrossRefGoogle Scholar
  130. 130.
    First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders — Patient Edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, New York State Psychiatric Institute, 1995Google Scholar
  131. 131.
    Evans SM, Foltin RW, Fischman MW. Food “cravings” and the acute effects of alprazolam on food intake in women with premenstrual dysphoric disorder. Appetite 1999 Jun; 32(3): 331–49PubMedCrossRefGoogle Scholar
  132. 132.
    Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991 Aug; 78(2): 177–81PubMedGoogle Scholar
  133. 133.
    Freeman EW, Stout AL, Endicott J, et al. Treatment of premenstrual syndrome with a carbohydrate-rich beverage. Int J Gynecol Obstet 2002; 77(3): 253–4CrossRefGoogle Scholar
  134. 134.
    De Souza MC, Walker AF, Robinson PA, et al. A synergistic effect of a daily supplementation for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med 2000 Mar; 9(2): 131–9PubMedCrossRefGoogle Scholar
  135. 135.
    Sayegh R, Schiff I, Wurtman J, et al. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. Obstet Gynecol 1995 Oct; 86 (4 Pt 1): 520–8PubMedGoogle Scholar
  136. 136.
    Walker AF, De Souza MC, Vickers MF, et al. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health 1998 Nov;7(9): 1157–65PubMedCrossRefGoogle Scholar
  137. 137.
    Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995 Jul; 274(1): 51–7PubMedCrossRefGoogle Scholar
  138. 138.
    Freeman EW, Sondheimer SJ, Sammel MD, et al. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry 2005 Jun; 66(6): 769–73PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Sarah Canning
    • 1
  • Mitch Waterman
    • 1
  • Nic Orsi
    • 2
  • Julie Ayres
    • 3
  • Nigel Simpson
    • 2
  • Louise Dye
    • 1
  1. 1.Institute of Psychological Sciences, University of LeedsLeedsUK
  2. 2.Perinatal Research Group, The YCR and Liz Dawn Pathology and Translational Sciences Centre, Leeds Institute of Molecular MedicineSt James’s University HospitalLeedsUK
  3. 3.Rosalind Bolton PMS Clinic, St James’s University HospitalLeedsUK

Personalised recommendations